{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:16:55Z","timestamp":1768083415594,"version":"3.49.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2001,11,13]]},"DOI":"10.1212\/wnl.57.9.1566","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:57:00Z","timestamp":1336917420000},"page":"1566-1570","source":"Crossref","is-referenced-by-count":72,"title":["Randomized pilot trial of \u03b2INF1a (Avonex) in patients with inclusion body myositis"],"prefix":"10.1212","volume":"57","author":[{"name":"The Muscle Study Group*","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<970::AID-MUS20>3.0.CO;2-I"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390615"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0925-4439(92)90059-V"},{"key":"e_1_3_2_5_2","first-page":"A331.","volume":"48","year":"1997","unstructured":"Yang CC, Alverax RB, Engel WK, Askanas V. Nitric oxide induced oxidative stress in the muscle fibres of hereditary inclusion body myopathy and sporadic inclusion body myositis. Neurology . 1997; 48: A331.Abstract.","journal-title":"Neurology"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380504"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530240033013"},{"key":"e_1_3_2_8_2","first-page":"1265","volume":"43","year":"1993","unstructured":"Askanas V, Engel WK, Alverez RB. Enhanced detection of Congo -red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer disease using fluorescence technique. Neurology . 1993; 43: 1265\u20131267.","journal-title":"Neurology"},{"key":"e_1_3_2_9_2","first-page":"1280","volume":"145","year":"1994","unstructured":"Sarkozi B, Askanas V, Engel WK. Abnormal accumulations of prion protein mRNA in muscle fibers of patients with sporadic inclusion body myositis and hereditary inclusion body myopathy. Am J Pathol . 1994; 145: 1280\u20131284.","journal-title":"Am J Pathol"},{"key":"e_1_3_2_10_2","first-page":"177","volume":"144","year":"1994","unstructured":"Askanas V, Engel WK, Bilak M, et al. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain containing hyperphosphorylated tau. Am J Pathol . 1994; 144: 177\u2013187.","journal-title":"Am J Pathol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390122"},{"key":"e_1_3_2_12_2","unstructured":"Engel   AG Hohlfield   R Banker   BQ.   Polymyositis and dermatomyositis. In:  Engel  AG Franzini\u2013Armstrong  C eds.  Myology.   2nd ed.   New York:   McGraw\u2013Hill 1994:  1335\u20131383."},{"key":"e_1_3_2_13_2","unstructured":"Engel   AG Arahata   K Emslie Smith   A.   Immune effector mechanisms in inflammatory myopathies. In:  Waksman  BH ed.  Immunologic mechanisms in neurologic and psychiatric disease.   New York:   Raven 1990:  141\u2013157."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/112.3.727"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199801)21:1<115::AID-MUS15>3.0.CO;2-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.10.2030"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-199410000-00013"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-000-0019-9"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.7.1302"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Engel   WK Askanas   V.   Treatment of inclusion-body myositis and hereditary inclusion-body myopathy with reference to pathogenic mechanisms: personal experience. In:  Askanas  V Serratrice  G eds.  Inclusion body myositis.   Cambridge:   Cambridge University Press 1998:  351\u2013382.","DOI":"10.1001\/archneur.55.7.915"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.3.712"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.8.1516"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410370105"},{"key":"e_1_3_2_24_2","first-page":"22","volume":"5","year":"1996","unstructured":"Cirelli R, Herne K, Tyring SK. Interferons: an overview of their pharmacology. Clin Immunother . 1996; 5: 22\u201330.","journal-title":"Clin Immunother"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/59.2.164"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.1.65"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390304"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"e_1_3_2_29_2","first-page":"I15.","volume":"246","year":"1999","unstructured":"Paty DW. Results of the 3 year double-blind, placebo controlled study of interferon beta-1a (Rebif) in secondary progressive multiple sclerosis. J Neurol . 1999; 246 (suppl I): I15.","journal-title":"J Neurol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.655"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/003329417403403s01"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/74.3.253"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.3.409"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/72.2.105"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.1.38"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880040304"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5.1402"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.3_Part_1.520"},{"key":"e_1_3_2_39_2","first-page":"320.","volume":"36","year":"1994","unstructured":"Tawil R, Herr BE, Moxley RT, et al. Dual energy x-ray absorptiometry: quantifying muscle mass in therapeutic trials. Ann Neurol . 1994; 36: 320.Abstract.","journal-title":"Ann Neurol"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-097X.1989.tb00989.x"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550020045014"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5.1266"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199714010-00005"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.1999.tb00367.x"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(00)00310-2"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.57.9.1566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T12:03:07Z","timestamp":1711540987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.57.9.1566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,13]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,11,13]]}},"alternative-id":["10.1212\/WNL.57.9.1566"],"URL":"https:\/\/doi.org\/10.1212\/wnl.57.9.1566","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11,13]]}}}